|
|
Post by mnholdem on Jul 12, 2018 8:57:54 GMT -5
David Kendall MD, Chief Medical Officer for MannKind Corporation, recently made a remarkable statement - which he reaffirmed at a recent investor's conference - that even though there have been 60+ clinical trials and nearly 3 dozen pre-clinical trials that evaluate Afrezza over the past 20 years, involving over 5,000 patients, MannKind has released 10 medical publications related to only 6 trials.
Kendall referred to the unpublished data as "Veins of Gold" and it sounds like he is planning to release many publications in the coming months and years.
Currently, 4 poster presentations have been accepted for the European Association for the Study of Diabetes 2018 Meeting in Berlin Oct 1-5, 2018. One of those presentations, highlighted in the graphic below, is totally new. Dr. Kendall will be producing evidence that diabetes, itself, has a more detrimental effect on pulmonary function than does Inhaled Technosphere® Insulin.
David talked a bit about this data at the 46-minute mark of his recent presentation. Link: lifesci.rampard.com/20180627/player.html
It hasn't escaped my attention that David Kendall's name is listed among the authors for those presentations whose studies were completed years ago and for which results were never published. For example, a few months ago, Kendall mentioned that MannKind was in possession of volumes of CT-SCAN data which, IMO, will likely form the basis of the first listed EASD2018 presentation on pulmonary function.
---
So, it appears that MannKind's new CMO and his team have been busy digging through years of clinical data from multiple Afrezza trials and are, indeed, unearthing veins of gold which will be extracted, refined and then presented to the medical community. I suspect that the EASD Pulmonary Function presentation will be only one of many future publications as David Kendall's team continues to dig through and analyze the Afrezza trial data.
As a long time investor, I'm looking forward to seeing what else the new CMO digs up.
 |
|
|
|
Post by tw12 on Jul 12, 2018 9:25:41 GMT -5
Thanks, mn, for your continued keen and much appreciated investigations!
|
|
|
|
Post by agedhippie on Jul 12, 2018 9:42:24 GMT -5
David Kendall MD, Chief Medical Officer for MannKind Corporation, recently made a remarkable statement - which he reaffirmed at a recent investor's conference - that even though there have been 60+ clinical trials and nearly 3 dozen pre-clinical trials that evaluate Afrezza over the past 20 years, involving over 5,000 patients, MannKind has released 10 medical publications related to only 6 trials.
Kendall referred to the unpublished data as "Veins of Gold" and it sounds like he is planning to release many publications in the coming months and years.
Currently, 4 poster presentations have been accepted for the European Association for the Study of Diabetes 2018 Meeting in Berlin Oct 1-5, 2018. One of those presentations, highlighted in the graphic below, is totally new. Dr. Kendall will be producing evidence that diabetes, itself, has a more detrimental effect on pulmonary function than does Inhaled Technosphere® Insulin.
David talked a bit about this data at the 46-minute mark of his recent presentation. Link: lifesci.rampard.com/20180627/player.html
It hasn't escaped my attention that David Kendall's name is listed among the authors for those presentations whose studies were completed years ago and for which results were never published. For example, a few months ago, Kendall mentioned that MannKind was in possession of volumes of CT-SCAN data which, IMO, will likely form the basis of the first listed EASD2018 presentation on pulmonary function.
---
So, it appears that MannKind's new CMO and his team have been busy digging through years of clinical data from multiple Afrezza trials and are, indeed, unearthing veins of gold which will be extracted, refined and then presented to the medical community. I suspect that the EASD Pulmonary Function presentation will be only one of many future publications as David Kendall's team continues to dig through and analyze the Afrezza trial data.
As a long time investor, I'm looking forward to seeing what else the new CMO digs up.
I think that was the data that was published previously in this paper ( Pulmonary function over 2 years in diabetic patients treated with prandial inhaled Technosphere Insulin or usual antidiabetes treatment: a randomized trial.) What they have done is added that there are other things that have more impact on lung function. Superficially that reads as it's bad, but not as bad as other possibles. The paper, and I am guessing the trial, says that there is minimal lung function change, but that's not very eye catching! |
|
|
|
Post by centralcoastinvestor on Jul 12, 2018 9:45:34 GMT -5
If I’m not mistaken, I believe Dr. Kendall stated that there would be an article coming out in a publication in July. I have no idea which publication but I am hoping to see something come out soon.
|
|
|
|
Post by peppy on Jul 12, 2018 9:48:16 GMT -5
Under the topic veins of gold....
I believe the Mike C or Dr. Kendall said the STAT Sudy would be published ~ 1 week after the ADA.
Has anyone seen it yet?
How would it be accessed?
|
|
|
|
Post by mango on Jul 12, 2018 11:05:57 GMT -5
Under the topic veins of gold.... I believe the Mike C or Dr. Kendall said the STAT Sudy would be published ~ 1 week after the ADA. Has anyone seen it yet? How would it be accessed? It will be made available shortly per MC. |
|
|
|
Post by mnholdem on Jul 12, 2018 11:37:24 GMT -5
If you go to 1:23:22 of the presentation (link above) Castagna and Kendall stated that publication "will be in mid-July". It was the first question of the Q&A following their presentation. They did not state a specific date, though. |
|
|
|
Post by centralcoastinvestor on Jul 12, 2018 11:40:44 GMT -5
If you go to 1:23:22 of the presentation (link above) Castagna and Kendall stated that publication "will be in mid-July". It was the first question of the Q&A following their presentation. They did not state a specific date, though. So any day now. I’m actually kind of excited to see which publication it is and the content of the write up. It’s just the beginning. |
|
|
|
Post by otherottawaguy on Jul 12, 2018 13:50:25 GMT -5
NEJM???
I can hope can't I?
OOG
|
|
|
|
Post by centralcoastinvestor on Jul 12, 2018 14:09:29 GMT -5
NEJM??? I can hope can't I? OOG Please, please, please. Fingers crossed. |
|
|
|
Post by chillymutt on May 15, 2019 14:23:48 GMT -5
Where are those veins of gold?
|
|
|
|
Post by mnholdem on May 15, 2019 15:10:40 GMT -5
Where are those promised publications? Another example of the CEO’s Marketing Director not delivering results. Based on her only published article, I think she needs to hire some experienced writers.
|
|
|
|
Post by lennymnkd on May 15, 2019 16:43:39 GMT -5
How are we not on THE CNBC disrupters list .
|
|
|
|
Post by boca1girl on May 15, 2019 16:49:19 GMT -5
How are we not on THE CNBC disrupters list . That was for non-public companies I believe. I suggested Vdex apply the last two years. |
|
|
|
Post by boca1girl on May 15, 2019 16:53:55 GMT -5
Where are those promised publications? Another example of the CEO’s Marketing Director not delivering results. Based on her only published article, I think she needs to hire some experienced writers. Dr. K. said they have 9 (?) draft articles for submission at the ASM and thanked his medical team for their efforts. I don’t remember him mentioning publishing dates but assumed this year. |
|
